Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has demonstrated that it can predict the outcome of Phase II to Phase III clinical trial success using its proprietary transformer-based AI clinical trial prediction tool called inClinico with a high degree of accuracy.
TRYP THERAPEUTICS AND EXOPHARM LIMITED ANNOUNCE COMPLETION OF PLAN OF ARRANGEMENT – Biotech Investments
, 05/01/2024 / 15:53, EST/EDT – EQS Newswire – Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange,
May 2, 2024